Sign in →

EPIC ORDER CODE LAB915 Hepatitis C Virus Genotype, Serum

Additional Codes

SQ: HCVG

Reporting Name

HCV Genotype, S

Useful For

Determining hepatitis C virus (HCV) genotype (1 to 5) to guide antiviral therapy in patients with chronic hepatitis C

 

Differentiating between HCV subtypes 1a and 1b

 

This assay should not be used as a screening test for HCV infection. It should be performed only on specimens obtained from patients confirmed to have HCV RNA levels in serum of 500 IU/mL or higher.

Testing Algorithm

Specimens either generating indeterminate genotype results, results with multiple or mixed hepatitis C virus genotypes (eg, 1, 5; 1, 2; or 1, 5), or those containing genotype 1 with no subtype will be automatically evaluated with by genotype resolution at an additional charge.

 

The following algorithms are available:

-Chronic Hepatitis C Treatment and Monitoring Algorithm: Direct Antiviral Antigen (DAA) Combination

-Hepatitis C: Testing Algorithm for Screening and Diagnosis

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Serum SST


Shipping Instructions


Ship specimen frozen on dry ice only. If shipment will be delayed for more than 3 days, freeze serum at -20° C or colder (up to 42 days) until shipment on dry ice.



Specimen Required


Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube: Serum gel (red-top tubes are not acceptable)

Submission Container/Tube: Plastic vial

Specimen Volume: 5 mL

Collection Instructions:

Within 2 hours of collection, centrifuge and aliquot serum into a plastic vial.

Additional Information:

1. This test requires a minimum hepatitis C virus viral load of 500 IU/mL within the 30 days preceding collection.

2. Serum specimens previously submitted to other laboratories for non-microbiology tests are not acceptable for add-on test requests due to possible sample-to-sample carryover from automation used for those tests.


Specimen Minimum Volume

1.5 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum SST Frozen (preferred) 42 days ALIQUOT TUBE
  Refrigerated  72 hours ALIQUOT TUBE

Reference Values

Undetected

Day(s) Performed

Monday through Friday

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

87902

LOINC Code Information

Test ID Test Order Name Order LOINC Value
HCVG HCV Genotype, S 32286-7

 

Result ID Test Result Name Result LOINC Value
81618 HCV Genotype, S 32286-7

Clinical Information

Unique nucleotide sequences of certain regions (eg, 5'-noncoding, core, NS5b) of the hepatitis C virus (HCV) genome allow classification of HCV into 6 major genotypes or clades (1-6), based on the most recently proposed HCV genotype nomenclature. In the United States, the most frequently encountered HCV genotypes are 1a and 1b, followed by genotypes 2 and 3. Worldwide geographic distribution, disease outcome, and response to antiviral therapy differ among the genotypes. Therefore, reliable methods for genotype determination are important for proper selection of antiviral therapy and optimal patient management. Infections with HCV genotypes 2 and 3 have better therapeutic response rates (80%-90%) than genotypes 1 and 4 (40%-50%) to previous standard combination therapy (ribavirin plus pegylated interferon alpha-2a or alpha-2b). Duration of such combination therapy is 24 weeks for chronic HCV genotype 2 and 3 infections in patients who show early virologic response (>2 log or 100-fold decrease in HCV RNA or no detectable HCV RNA at week 12 of therapy), while patients with chronic HCV genotype 1 and 4 infections receive a minimum of 48 weeks of such combination therapy if early virologic response is achieved (undetectable HCV RNA at week 4 of therapy).

 

Therapeutic response rates for HCV genotype 1 infection are improved significantly (80%-90%) when oral direct acting antiviral agents (eg, daclatasvir, sofosbuvir, ledipasvir + sofosbuvir, velpatasvir + sofosbuvir, glecaprevir + pibrentasvir, elbasvir + grazoprevir, velpatasvir + voxilaprevir + sofosbuvir) are added or used in lieu of interferon-based combination therapy.

 

The American Association for the Study of Liver Diseases and Infectious Disease Society of America recommendations for testing, managing, and treating hepatitis C are available at www.hcvguidelines.org/contents.

 

The following algorithms are available:

-Chronic Hepatitis C Treatment and Monitoring Algorithm: Direct Antiviral Antigen (DAA) Combination

-Hepatitis C: Testing Algorithm for Screening and Diagnosis

Interpretation

Hepatitis C virus (HCV) genotyping result

Interpretation

Resolution test (reflex test) ordered?

1a

1a is the definitive subtype/genotype

No

1b

1b is the definitive subtype/genotype

No

2

2 is the definitive genotype

No

3

3 is the definitive genotype

No

4

4 is the definitive genotype

No

5

5 is the definitive genotype

No

1

A definitive genotype/subtype (1a, 1b, 6) could not be assigned. Resolution testing ordered.

Yes

1a, 2 (any 2 genotypes)

Result may be due to mixed genotype infection, recombination of HCV genotypes, or assay probe cross-reactivity.

No

1, 3 (2 genotypes with a 1 no subtype)

Result may be due to mixed genotype infection, recombination of HCV genotypes, or assay probe cross-reactivity. Resolution testing ordered.

Yes

HCV not detected

Assay failed to detect HCV RNA.

No

Indeterminate (undetermined genotype)

HCV RNA detected, but genotype could not be determined. Resolution testing ordered.

Yes

Indeterminate (mix)

Result may be due to mixed genotype infection, recombination of HCV genotypes, or assay probe cross-reactivity.

No

 

An "Undetected" result indicates the absence of detectable hepatitis C virus (HCV) RNA in the specimen.

 

An "Indeterminate" result may be due to one or more of the following causes:

1. Low HCV RNA level (ie, <500 IU/mL)

2. HCV genotype 6

3. Probe reactivity with multiple HCV genotypes

4. Variation in patient's HCV target sequences with mismatches to polymerase chain reaction primers and/or probes.

Specimens generating indeterminate results with this assay will be automatically evaluated with the subsequent test HCVGR / Hepatitis C Virus Genotype Resolution, Serum.

 

An HCV genotype result of "1" without a subtype result may be due to one or more of the following causes:

1. Low HCV RNA level (ie, <500 IU/mL)

2. Probe reactivity with multiple genotype 1 subtypes

3. Variation in HCV genotype 1 target sequence

4. Misclassification of some true genotype 6 strains

 

This assay can differentiate between HCV subtypes 1a and 1b. However, subtypes are not reported for HCV genotypes 2 to 5 due to limitations of the current genotyping assay in accurately differentiating the various subtypes of these genotypes.

 

Results with multiple or mixed HCV genotypes (eg, 1, 5; 1a, 2; or 3, 5) may be due to mixed genotype infection or assay probe cross-reactivity. Only those specimens with multiple or mixed genotype results containing genotype 1 but no subtype will be automatically evaluated with the subsequent test HCVGR / Hepatitis C Virus Genotype Resolution, Serum.

Clinical Reference

1. Germer JJ, Mandrekar JN, Bendel JL, et al: Hepatitis C virus genotypes in clinical specimens tested at a national reference testing laboratory in the United States. J Clin Microbiol. 2011;49(8):3040-3043

2. American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Accessed August 21, 2024. Available at www.hcvguidelines.org

Method Description

Sample Preparation:

The Abbott mSample Preparation System kit is used with the Abbott m2000sp, an automated sample preparation system using the magnetic microparticle processes to extract and purify viral nucleic acids from human serum specimens. An internal control is incorporated in the nucleic acid extraction and purification procedure for processing the assay controls and clinical specimens. After capture of nucleic acids onto magnetic microparticles, the microparticles are washed to remove unbound sample components. Then, the bound nucleic acids are eluted from the microparticles, and the eluates are transferred to a 96-well microtiter plate containing polymerase chain reaction (PCR) mastermix reagents for amplification and detection.

 

Amplification, Detection, and Genotyping:

The Abbott RealTime HCV Genotype II assay is used to amplify the 5' noncoding (5' NC), nonstructural 5b (NS5b), and core regions of the hepatitis C virus (HCV) genome, with several PCR primer sets that are optimized to amplify all HCV isolates. An internal control primer set is included to amplify a portion of the hydroxypyruvate reductase gene of the pumpkin plant, Cucurbita pepo. The assays positive control is an armored RNA particle diluted in negative human plasma.

 

During the amplification reaction, complementary DNA (cDNA) sequences are generated from the target RNA sequences by the reverse transcriptase activity of the thermostable rTth DNA polymerase. First, the HCV and internal control reverse primers anneal to their respective target sequences and are extended during a prolonged incubation period. After a denaturation step, in which the temperature of the reaction is raised above the melting point of the double-stranded cDNA:RNA product, a second primer anneals to the cDNA strand and is extended by the DNA polymerase activity of the rTth enzyme to create a double-stranded DNA product. During each round of thermal cycling, amplification products dissociate to single strands at a high temperature, allowing primer annealing and extension as the temperature is lowered. Exponential amplification of the product is achieved through repeated cycling between high and low temperatures, resulting in a billion-fold or greater amplification of target sequences. Fluorescent probes specific for HCV genotypes 1 to 5 and subtypes 1a and 1b anneal to the amplified sequence products in 4 separate reaction wells for each specimen.(Package insert: RealTime HCV Genotype II. Abbott Molecular Inc; R1, 06/2013)

Report Available

1 to 6 days

Specimen Retention Time

2 months

Reject Due To

Gross hemolysis OK
Gross lipemia OK

Method Name

Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) followed by Hybridization with Sequence-Specific, Fluorescent-Labeled Oligonucleotide Probes

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
HCVGR HCV Genotype Resolution, S No No

Forms

If not ordering electronically, complete, print, and send 1 of the following:

-Gastroenterology and Hepatology Test Request (T728)

-Microbiology Test Request (T244)